A Phase II Clinical Trial to Study the Efficacy and Safety of a New Drug P276-00 in Treatment of Recurrent and/or Locally Advanced Head and Neck Cancer (MONARCH)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00824343 |
Recruitment Status :
Completed
First Posted : January 16, 2009
Last Update Posted : July 10, 2013
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Squamous Cell Carcinoma of Head and Neck | Drug: P276-00 | Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 86 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | An Open Label, Multicenter Phase II Study to Evaluate Efficacy and Safety of P276-00 in Indian Subjects With Recurrent, Metastatic or Unresectable Locally Advanced Squamous Cell Carcinoma of Head and Neck |
Study Start Date : | September 2008 |
Actual Primary Completion Date : | April 2011 |
Actual Study Completion Date : | June 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Single P276-00 arm
This is a single experimental arm study
|
Drug: P276-00
For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment. |
- Response rate [ Time Frame: Tumor measurements to be undertaken at baseline and at the end of every 2 cycles. Response evaluation to be performed on the basis of RECIST criteria ]
- Duration of response, Progression free survival (PFS), Time to progression (TTP), PFS at one year, Overall survival (OS) at one year [ Time Frame: Tumor measurements at the end of every 2 cycles. Follow up for survival status every 4 weeks after discontinuation of protocol treatment till one year of cycle 1 day 1 ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age more than or equal to 18 years
- Subjects with histologically or cytologically confirmed SCCHN that is recurrent and/or metastatic and judged incurable by surgery and/or radiation therapy and with zero to one line of chemotherapy for recurrent or metastatic disease at least 60 days prior to study entry.
- Measurable disease, defined as at least one unidimensionally measurable lesion ≥ 20 mm by conventional techniques or ≥10 mm by spiral computerized tomography (CT) scan or magnetic resonance imaging (MRI)
- Tumor that is accessible to biopsy
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
- Life expectancy of at least three months
- Hemoglobin ≥ 8.0 gm/dL
- Absolute neutrophil count (ANC) ≥ 1000/mm3
- Platelet count ≥ 50,000/mm3
- Total bilirubin ≤1.5X institutional upper limit of normal (ULN)
- Serum AST ≤ 3X institutional ULN
- Serum ALT ≤ 3X institutional ULN
- Serum creatinine ≤1.5X institutional ULN
- Ability to understand and the willingness to sign a written informed consent document (ICD)
Exclusion Criteria:
- Nasopharyngeal carcinoma
- Prior treatment with P276-00 or other Cyclin dependent kinase (CDK) targeting agents
- History of allergic reactions attributed to compounds of similar chemical composition to P276-00
- Subjects who have received radiotherapy, chemotherapy or biologic/targeted anticancer agents within 60 days prior to Day 1 of study drug administration or have not recovered from adverse effects of any prior radiotherapy, chemotherapy or biologic/targeted agents.
- More than one chemotherapy regimen for the recurrent or metastatic disease
- Subjects who had received any other investigational drug within 1 month or within five half-lives of the other investigational agent, whichever is longer prior to Day 1 of study drug administration
- Subjects with QTc > 450 msec on 12 lead standard electrocardiogram (ECG)
- History of unstable angina or myocardial infarction or stroke within previous 6 months
- Subjects with uncontrolled inter-current illness including, but not limited to active infection, symptomatic congestive heart failure, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
- Subjects known to be suffering from infection with HIV, Tuberculosis, Hepatitis C or Hepatitis B
- Known brain metastasis
- History of prior malignancy except for curatively treated basal cell or squamous cell carcinoma of skin, in situ cervical cancer, in situ breast cancer, in situ prostate cancer or any other cancer for which the subject has been disease-free for at least 3 years
- Women who are pregnant or lactating
- Women of childbearing potential [defined as sexually mature women who have not undergone hysterectomy or who have not been naturally postmenopausal for at least 24 consecutive months (i.e. who have had menses any time in the preceding 24 consecutive months)] and men, not agreeing to use adequate contraception (e.g., hormonal or barrier method of birth control or abstinence) prior to study entry (after signing the ICD), during the period of study participation and for at least 4 weeks after withdrawal from the study, unless they are surgically sterilized
- Any condition, including laboratory abnormalities, that in the opinion of the Investigator places the subject at an unacceptable risk or deems the subject not suitable for participation in the study

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00824343
India | |
Bharath Hospital & Institute of Oncology, Mysore | |
Mysore, Karnataka, India, 570017 | |
Regional Cancer Centre | |
Trivandrum, Kerala, India, 695011 | |
Kashyap Nursing Home | |
Mumbai, Maharashtra, India, 400014 | |
Jaslok Hospital, Mumbai | |
Mumbai, Maharashtra, India, 400026 | |
Central India Cancer Research Institute, | |
Nagpur, Maharashtra, India, 440010 | |
Deenanath Mangeshkar Hospital & Research Centre | |
Pune, Maharashtra, India, 411004 | |
Bhagwan Mahaveer Cancer Hospital & Research Centre, Dept. Of Medical Oncology, Jaipur | |
Jaipur, Rajasthan, India, 302 017 | |
V. N. Cancer Centre, GKNM Hospital, | |
Coimbatore, Tamilnadu, India, 641037 | |
Dept. Of Surgical Oncology, CSM Medical University, Lucknow | |
Lucknow, UttarPradesh, India, 226003 |
Principal Investigator: | Dr. Ajay Mehta | Director and Onco-Surgeon, Central India Cancer Research Institute, Nagpur | |
Principal Investigator: | Dr. M S Vishveshwara | Radiation Oncologist, Bharat Hospital Institute of Oncology, Mysore | |
Principal Investigator: | Dr. Sanjeev Misra | Oncosurgeon, Department of Surgical Oncology, CSM Medical University, Lucknow | |
Principal Investigator: | Dr. Rejnish Kumar | Associate Professor, Regional Cancer Centre, Trivandram | |
Principal Investigator: | Dr. Lalit Mohan Sharma | Consultant Medical Oncologist, Bhagwan Mahavir Cancer Hospital and Research Centre, Jaipur | |
Principal Investigator: | Dr. Maheboob Basade | Medical Oncologist, Jaslok Hospital, Mumbai | |
Principal Investigator: | Dr. Nilesh Lokeshwar, MD, DM | Medical Oncologist | |
Principal Investigator: | Dr. Chetan Deshmukh, MD, DM | Medical Oncologist, Deenanath Mangeshkar Hospital and Research Centre, Pune, India | |
Principal Investigator: | Dr. M Nagarajan, MD | Radiation Oncologist, V. N. Cancer Centre, GKNM Hospital, Coimbatore, India |
Responsible Party: | Piramal Enterprises Limited |
ClinicalTrials.gov Identifier: | NCT00824343 |
Other Study ID Numbers: |
P276-00/21/08 |
First Posted: | January 16, 2009 Key Record Dates |
Last Update Posted: | July 10, 2013 |
Last Verified: | July 2013 |
Carcinoma Carcinoma, Squamous Cell Squamous Cell Carcinoma of Head and Neck Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type |
Neoplasms Neoplasms, Squamous Cell Head and Neck Neoplasms Neoplasms by Site |